JP2003310211A - Food and medicine for improving antidement effect and memory learning comprising silkworm and wild silkworm powder - Google Patents
Food and medicine for improving antidement effect and memory learning comprising silkworm and wild silkworm powderInfo
- Publication number
- JP2003310211A JP2003310211A JP2002158295A JP2002158295A JP2003310211A JP 2003310211 A JP2003310211 A JP 2003310211A JP 2002158295 A JP2002158295 A JP 2002158295A JP 2002158295 A JP2002158295 A JP 2002158295A JP 2003310211 A JP2003310211 A JP 2003310211A
- Authority
- JP
- Japan
- Prior art keywords
- silkworm
- effect
- wild
- memory learning
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、ヒトを含めた哺乳
動物の抗痴呆効果ならびに記憶学習効果の向上に利用す
る方法に関する。TECHNICAL FIELD The present invention relates to a method for improving the anti-dementia effect and memory learning effect of mammals including humans.
【０００２】[0002]
【従来の技術】カイコおよび野蚕のシルクパウダーは、
各種の製造技術で粉末化されており、その低分子粉末化
されたもののアミノ酸構成はフィブロインタンパク質で
あることから既知のアミノ酸構成物である。その利用法
として、食品ならびに化粧品などに活用されている。2. Description of the Related Art Silk powder of silkworm and silkworm is
It has been powdered by various manufacturing techniques, and the amino acid composition of the powdered low molecular weight product is a known amino acid composition because it is a fibroin protein. As its usage, it is used in foods and cosmetics.
【０００３】しかし、いまだにカイコおよび野蚕のシル
クパウダーに抗痴呆効果ならびに記憶学習向上効果があ
るということについては明らかにされていない。However, it has not yet been clarified that silkworm and silkworm silk powder has an anti-dementia effect and an effect of improving memory learning.
【０００４】[0004]
【発明が解決しようとする課題】そこで、グリシン、ア
ラニン、セリン、チロシンなどのフィブロインタンパク
質の構成アミノ酸が豊富に存在することから、カイコお
よび野蚕のシルクパウダーに抗痴呆効果ならびに記憶学
習向上効果が期待される。Therefore, since the constituent amino acids of fibroin proteins such as glycine, alanine, serine, and tyrosine are abundant, silkworm and silkworm silk powders are expected to have anti-dementia effect and memory learning improvement effect. To be done.
【０００５】[0005]
【課題を解決するための手段】既知の製造法（酸加水分
解、酵素加水分解）に従って作製したカイコおよび野蚕
シルクパウダーをマウス（５週齢のＩＣＲ系雌性）に水
溶液として経口的に自由摂取させ、対照区として、水道
水とウシ血清アルブミン（ブラシ−ボとして採用）水溶
液を経口投与する。[Means for Solving the Problems] Silkworms and wild silkworm silk powder prepared according to known production methods (acid hydrolysis, enzymatic hydrolysis) are allowed to be freely orally taken as an aqueous solution by mice (5-week-old ICR females). As a control, tap water and an aqueous solution of bovine serum albumin (used as a brush) are orally administered.
【０００６】[0006]
【発明の実施の形態】摂取開始から３０日後にステップ
スルー型受動的回避実験を２日間行うものである。BEST MODE FOR CARRYING OUT THE INVENTION A step-through type passive avoidance experiment is conducted for 2 days 30 days after the start of ingestion.
【０００７】受動的回避反応として、マウスを水区（ｎ
＝２８）、シルクパウダー区（ｎ＝３１）、牛血清アル
ブミン区（ｎ＝２２）、の３グループに分ける。[0007] As a passive avoidance reaction,
= 28), silk powder group (n = 31), and bovine serum albumin group (n = 22).
【０００８】実験１日目は、前獲得試行測定１５分後に
ギロチンドアを閉めている明室にマウスを入れる。３０
秒後にドアを開け、暗室に入るまでの時間を測定し（以
下、獲得試行とする）、入ったらドアを閉め電気刺激
（０．５Ｍａ、４秒）を与える。なお、暗室に入るまで
の時間はマウスの後ろ足が完全に入った時点で暗室に進
入したものとして測定する。２４時間後（実験２日目）
に、ドアを閉めている明室にマウスを入れる。３０秒後
にドアを開け、暗室に入るまでの時間を測定する（以
下、投与前試行とする）。投与前試行が１８０秒以下で
あったマウスは、基準不達成マウスであるとして以後の
再生試行は行わない。On the first day of the experiment, the mouse is placed in the light room with the guillotine door closed 15 minutes after the pre-acquisition trial measurement. Thirty
After 2 seconds, the door is opened and the time until entering the dark room is measured (hereinafter referred to as acquisition trial). When the door is entered, the door is closed and electrical stimulation (0.5 Ma, 4 seconds) is given. The time until entering the dark room is measured as if the hind paws of the mouse had completely entered the dark room. 24 hours later (2nd day of experiment)
Then, put the mouse in the light room with the door closed. After 30 seconds, the door is opened and the time until entering the dark room is measured (hereinafter referred to as pre-administration trial). Mice that had a pre-administration trial of 180 seconds or less were regarded as non-achievement mice, and subsequent regeneration trials were not performed.
【０００９】次に、一時的な痴呆を起すｓｃｏｐｏｌａ
ｍｉｎｅを皮下注射し、１５分後にドアを閉めている明
室にマウスを入れ、３０秒後にドアを開け暗室に入るま
での時間を測定する（以下、再生試行とする）。この実
験では、ノンパラメトリック分析でデータ解析を行う。
同じ郡内の検定はＷｉｌｃｏｘｏｎの符号順位検定、異
なる群の間の検定はＭａｎｎ−ＷｈｉｔｎｅｙのＵ検定
を用いて有意差を調べる。Next, scopola which causes temporary dementia
Mine is subcutaneously injected, and 15 minutes later, the mouse is put in a light room with the door closed, and after 30 seconds, the time until the door is opened and the room enters the dark room is measured (hereinafter referred to as a reproduction trial). In this experiment, data analysis is performed by nonparametric analysis.
The Wilcoxon signed rank test is used for the test within the same group, and the Mann-Whitney U test is used for the test between different groups to check for significant differences.
【００１０】図１に示す実施例は、獲得試行、ｓｃｏｐ
ｏｌａｍｉｎｅ投与前試行、そして再生試行における記
憶能（秒）の結果である。その結果、ｓｃｏｐｏｌａｍ
ｉｎｅを体重１ｋｇあたり０．５ｍｇ各マウスに投与し
一時的な痴呆を起させたところ、シルクパウダー群と水
道水ならびにウシ血清アルブミンの間で、再生試行にお
いて反応潜時の有意差が認められる。＊＊Ｐ＜０．０
１，＊Ｐ＜０．０５は、再生試行におけるシルクパウダ
ー群として他の２グループで有意な差が認められる（Ｍ
ａｎｎ−ＷｈｉｔｎｅｙのＵ検定）。＃＃Ｐ＜０．０１
は、３グループの投与前試行と再生試行の間で有意な差
が認められる（Ｗｉｌｃｏｘｅｎの符号順位検定）。The embodiment shown in FIG. 1 uses the acquisition trial, scop.
It is a result of the memory capacity (second) in the trial before administration of olamine and the regeneration trial. As a result, scopolam
When ine was administered to each mouse at a dose of 0.5 mg per 1 kg of body weight to induce temporary dementia, a significant difference in reaction latency was observed between the silk powder group and tap water and bovine serum albumin in the regenerating trial. ** P <0.0
1, * P <0.05, a significant difference was observed between the other two silk powder groups in the regeneration trial (M
Ann-Whitney U test). ## P <0.01
Shows a significant difference between the pre-dose trials and the regeneration trials of the 3 groups (Wilcoxen's signed rank test).
【００１１】すなわち、マウス行動実験においてシルク
パウダー経口投与によって、一時的な痴呆を抑える効果
を有する。That is, in a mouse behavioral experiment, oral administration of silk powder has the effect of suppressing temporary dementia.
【００１２】[0012]
【発明の効果】本発明は、以上説明したような形態で実
施され、いかに記載されるような効果を泰する。The present invention is carried out in the form described above, and brings about the effects as described below.
【００１３】カイコならびに野蚕からのシルクパウダー
を含有させた食品および医薬品をヒトを含めた哺乳動物
に投与することにより、抗痴呆効果および記憶学習効果
を得ることができる。The anti-dementia effect and the memory learning effect can be obtained by administering foods and pharmaceuticals containing silkworm and silk powder from wild silkworm to mammals including humans.
【図１】摂取開始から３０日後にステップスルー型受動
回避実験を２日間行った成果図である。FIG. 1 is a diagram showing the results of performing a step-through type passive avoidance experiment for 2 days 30 days after the start of ingestion.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 山本 圭一郎 岩手県盛岡市上田三丁目18番８号 岩手大 学農学部内 (72)発明者 大内 順子 岩手県盛岡市上田三丁目18番８号 岩手大 学農学部内 Ｆターム(参考） 4B018 MD20 MD76 ME10 4C084 AA02 BA43 BA44 CA49 DB01 MA17 MA52 NA14 ZA15 ZA16 ─────────────────────────────────────────────────── ─── Continued front page (72) Inventor Keiichiro Yamamoto Iwate Univ. 3-18-8 Ueda, Morioka City, Iwate Prefecture Faculty of Agriculture (72) Inventor Junko Ouchi Iwate Univ. 3-18-8 Ueda, Morioka City, Iwate Prefecture Faculty of Agriculture F-term (reference) 4B018 MD20 MD76 ME10 4C084 AA02 BA43 BA44 CA49 DB01 MA17 MA52 NA14 ZA15 ZA16
Claims (2)
リシン、アラニン、セリン、チロシンのアミノ酸の繰り
返し配列から構成されるフィブロインタンパク質で、各
種の製造処理で低分子粉末化（遊離アミノ酸とオリゴペ
プチドから構成）された既知のアミノ酸構成に基づく生
産物である。これを利用することにより、抗痴呆効果な
らびに記憶学習向上のために食品および医療分野への応
用開発。1. Silk powder of silkworms and wild silkworms is a fibroin protein mainly composed of repeating sequences of amino acids of glycine, alanine, serine, and tyrosine, and is made into a low molecular weight powder (free amino acid and oligopeptide by various manufacturing processes). It is a product based on the known amino acid composition. By utilizing this, application development in the food and medical fields will be carried out to improve the anti-dementia effect and memory learning.
呆効果ならびに記憶学習向上効果があるということにつ
いては明らかにされていない。そこで、グリシン、アラ
ニン、セリン、チロシンなどのフィブロインタンパク質
の構成アミノ酸が豊富に存在することから、カイコおよ
び野蚕のシルクパウダーに抗痴呆効果ならびに記憶学習
向上を有することを特徴とする方法。2. It has not been clarified that silk powder of silkworm and wild silkworm has an anti-dementia effect and an effect of improving memory learning. Therefore, since the constituent amino acids of the fibroin protein such as glycine, alanine, serine and tyrosine are abundantly present, the silk powder of silkworm and wild silkworm has an anti-dementia effect and an improvement in memory learning.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002158295A JP2003310211A (en) | 2002-04-24 | 2002-04-24 | Food and medicine for improving antidement effect and memory learning comprising silkworm and wild silkworm powder |
| AU2002332302A AU2002332302A1 (en) | 2002-04-24 | 2002-09-05 | Foods and drugs containing silkworm and wild silkworm silk powder for antidementia effect and improving memorization learning |
| PCT/JP2002/009051 WO2003090775A1 (en) | 2002-04-24 | 2002-09-05 | Foods and drugs containing silkworm and wild silkworm silk powder for antidementia effect and improving memorization learning |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002158295A JP2003310211A (en) | 2002-04-24 | 2002-04-24 | Food and medicine for improving antidement effect and memory learning comprising silkworm and wild silkworm powder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2003310211A true JP2003310211A (en) | 2003-11-05 |
Family
ID=29267853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002158295A Pending JP2003310211A (en) | 2002-04-24 | 2002-04-24 | Food and medicine for improving antidement effect and memory learning comprising silkworm and wild silkworm powder |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2003310211A (en) |
| AU (1) | AU2002332302A1 (en) |
| WO (1) | WO2003090775A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009514783A (en) * | 2004-07-31 | 2009-04-09 | バイオグランド シーオー エル ティー ディー | Silk peptide for improving neuroprotection and nerve function efficacy and method for producing the same |
| JP2009280503A (en) * | 2008-05-19 | 2009-12-03 | Iwate Univ | Pharmacological use of cocoon of cricula trifenestrata |
| JP2012017287A (en) * | 2010-07-07 | 2012-01-26 | Iwate Univ | Therapeutic agent for senile disease |
| JP2012040010A (en) * | 2011-09-14 | 2012-03-01 | Biogrand Co Ltd | Use of composition as additive for food or functional food |
| WO2019225942A1 (en) * | 2018-05-23 | 2019-11-28 | 대한민국(농촌진흥청장) | Composition for improving memory or composition for preventing and treating alzheimer's disease, comprising cooked processed silkworm product having silk protein |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07112415B2 (en) * | 1991-02-19 | 1995-12-06 | 長濱産業株式会社 | Dressing with silk powder and manufacturing method thereof |
| JP2000093091A (en) * | 1998-09-25 | 2000-04-04 | Gakuei O | Wild silkworm water-soluble silk powder and its production |
| JP2000201643A (en) * | 1999-01-11 | 2000-07-25 | Eiko:Kk | Pickled ume containing silk protein hydrolyzate added thereto and its production |
-
2002
- 2002-04-24 JP JP2002158295A patent/JP2003310211A/en active Pending
- 2002-09-05 AU AU2002332302A patent/AU2002332302A1/en not_active Abandoned
- 2002-09-05 WO PCT/JP2002/009051 patent/WO2003090775A1/en active Application Filing
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009514783A (en) * | 2004-07-31 | 2009-04-09 | バイオグランド シーオー エル ティー ディー | Silk peptide for improving neuroprotection and nerve function efficacy and method for producing the same |
| JP4896017B2 (en) * | 2004-07-31 | 2012-03-14 | バイオグランド シーオー エル ティー ディー | Composition for improving brain disease or brain function |
| JP2009280503A (en) * | 2008-05-19 | 2009-12-03 | Iwate Univ | Pharmacological use of cocoon of cricula trifenestrata |
| JP2012017287A (en) * | 2010-07-07 | 2012-01-26 | Iwate Univ | Therapeutic agent for senile disease |
| JP2012040010A (en) * | 2011-09-14 | 2012-03-01 | Biogrand Co Ltd | Use of composition as additive for food or functional food |
| WO2019225942A1 (en) * | 2018-05-23 | 2019-11-28 | 대한민국(농촌진흥청장) | Composition for improving memory or composition for preventing and treating alzheimer's disease, comprising cooked processed silkworm product having silk protein |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003090775A1 (en) | 2003-11-06 |
| AU2002332302A1 (en) | 2003-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0770195A (en) | Sugar-modified interferon | |
| JP5096173B2 (en) | Rheumatoid arthritis inhibitor for oral intake | |
| JP2005527470A5 (en) | ||
| ES2932498T3 (en) | Compositions comprising the peptide WKDEAGKPLVK | |
| CN113499329A (en) | Application of isoliquiritigenin in preparing medicine for resisting neuritis | |
| JP2003310211A (en) | Food and medicine for improving antidement effect and memory learning comprising silkworm and wild silkworm powder | |
| CN102088992B (en) | Peptidyl diacylglycerides | |
| JPS5837285B2 (en) | It is very difficult to understand the situation. | |
| JP3973244B2 (en) | Use of a decapeptide having benzodiazepine-type activity for the manufacture of a medicament | |
| CN106061494A (en) | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions | |
| JPH03151400A (en) | Chemically modified allergens and their preparation | |
| Areshidze et al. | Anti-inflammatory effect of NICA-EM in rodent models of acute inflammation | |
| KR100266929B1 (en) | Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof. | |
| JPH0534341B2 (en) | ||
| JP2020169134A (en) | Prevention and/or treatment agents for allergic rhinitis | |
| JP2753938B2 (en) | Pharmaceutical composition for enhancing humoral immunity | |
| JP2001213897A (en) | Opioid peptide and method for producing the same | |
| Rimington | The chemistry of the proteins and amino acids | |
| JPH0534340B2 (en) | ||
| RU2305328C1 (en) | Method for modeling rheumatoid arthritis cases | |
| JP4586181B2 (en) | Protein stabilization method, protein stabilizer and protein-containing solution | |
| Pshennikova et al. | Adaptation to stress improves resistance to gastric damage during acute stress in Wistar rats and decreases resistance in August rats: role of serotonin | |
| JPH0520440B2 (en) | ||
| WO2001098363A3 (en) | Peptides for use in the immunotherapy of renal cell carcinoma | |
| BRPI0410460A (en) | t24 antigen for the immunological diagnosis of cysticercosis caused by taenia solium |